Brokerages expect that Halyard Health, Inc. (NYSE:HYH) will post earnings per share of $0.38 for the current quarter, according to Zacks. Four analysts have made estimates for Halyard Health’s earnings, with estimates ranging from $0.36 to $0.40. Halyard Health posted earnings of $0.45 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 15.6%. The firm is scheduled to announce its next earnings results on Wednesday, August 2nd.

On average, analysts expect that Halyard Health will report full year earnings of $1.85 per share for the current year, with EPS estimates ranging from $1.83 to $1.87. For the next fiscal year, analysts expect that the company will post earnings of $2.03 per share, with EPS estimates ranging from $1.98 to $2.09. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Halyard Health.

Halyard Health (NYSE:HYH) last issued its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.05. The company had revenue of $395.60 million during the quarter, compared to analysts’ expectations of $391.56 million. Halyard Health had a return on equity of 8.16% and a net margin of 2.40%. The business’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the business earned $0.53 earnings per share.

Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a report on Wednesday. BidaskClub cut Halyard Health from a “buy” rating to a “hold” rating in a report on Saturday. Finally, TheStreet raised Halyard Health from a “c” rating to a “b” rating in a report on Thursday, June 22nd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Halyard Health currently has an average rating of “Hold” and a consensus target price of $40.50.

Shares of Halyard Health (HYH) traded up 0.23% on Wednesday, hitting $39.01. The company’s stock had a trading volume of 170,032 shares. The stock’s 50-day moving average price is $37.60 and its 200-day moving average price is $38.35. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of 47.52 and a beta of 1.78. Halyard Health has a 52 week low of $31.59 and a 52 week high of $41.84.

COPYRIGHT VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/07/zacks-brokerages-expect-halyard-health-inc-nysehyh-will-post-earnings-of-0-38-per-share-updated-updated-updated.html.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock worth $226,229,000 after buying an additional 5,847,442 shares in the last quarter. Copper Rock Capital Partners LLC bought a new position in shares of Halyard Health during the first quarter worth approximately $26,763,000. Norges Bank bought a new position in shares of Halyard Health during the fourth quarter worth approximately $17,606,000. Dimensional Fund Advisors LP boosted its position in shares of Halyard Health by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,625,156 shares of the medical instruments supplier’s stock worth $99,992,000 after buying an additional 415,105 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Halyard Health by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock worth $165,711,000 after buying an additional 196,367 shares in the last quarter. 91.44% of the stock is currently owned by institutional investors.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Get a free copy of the Zacks research report on Halyard Health (HYH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.